Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37983945)

  • 21. CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non-Small Cell Lung Cancer.
    Prahallad A; Weiss A; Voshol H; Kerr G; Sprouffske K; Yuan T; Ruddy D; Meistertzheim M; Kazic-Legueux M; Kottarathil T; Piquet M; Cao Y; Martinuzzi-Duboc L; Buhles A; Adler F; Mannino S; Tordella L; Sansregret L; Maira SM; Graus Porta D; Fedele C; Brachmann SM
    Cancer Res; 2023 Dec; 83(24):4130-4141. PubMed ID: 37934115
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of LGR4 as a prognostic biomarker in KRAS-mutant lung adenocarcinoma: Evidence from integrated bioinformatics analysis.
    Dodin Y
    Medicine (Baltimore); 2023 Nov; 102(46):e36084. PubMed ID: 37986325
    [TBL] [Abstract][Full Text] [Related]  

  • 23. KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges.
    Moldvay J; Tímár J
    Pathol Oncol Res; 2023; 29():1611580. PubMed ID: 38239281
    [TBL] [Abstract][Full Text] [Related]  

  • 24. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
    Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
    Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRASG12C-Mutant Pancreatic and Lung Cancers.
    Khan HY; Nagasaka M; Aboukameel A; Alkhalili O; Uddin MH; Bannoura SF; Mzannar Y; Azar I; Beal EW; Tobon ME; Kim SH; Beydoun R; Baloglu E; Senapedis W; El-Rayes BF; Philip PA; Mohammad RM; Shields AF; Al Hallak MN; Azmi AS
    Mol Cancer Ther; 2023 Dec; 22(12):1422-1433. PubMed ID: 37703579
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BCL-X
    Khan S; Wiegand J; Zhang P; Hu W; Thummuri D; Budamagunta V; Hua N; Jin L; Allegra CJ; Kopetz SE; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
    J Hematol Oncol; 2022 Mar; 15(1):23. PubMed ID: 35260176
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification.
    Elkrief A; Odintsov I; Markov V; Caeser R; Sobczuk P; Tischfield SE; Bhanot U; Vanderbilt CM; Cheng EH; Drilon A; Riely GJ; Lockwood WW; de Stanchina E; Tirunagaru VG; Doebele RC; Quintanal-Villalonga Á; Rudin CM; Somwar R; Ladanyi M
    J Thorac Oncol; 2023 Sep; 18(9):1165-1183. PubMed ID: 37182602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impaired AKT signaling and lung tumorigenesis by PIERCE1 ablation in KRAS-mutant non-small cell lung cancer.
    Roh JI; Lee J; Sung YH; Oh J; Hyeon DY; Kim Y; Lee S; Devkota S; Kim HJ; Park B; Nam T; Song Y; Kim Y; Hwang D; Lee HW
    Oncogene; 2020 Sep; 39(36):5876-5887. PubMed ID: 32728173
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations.
    Jiang ZB; Huang J; Xie C; Li X; Liu L; He J; Pan H; Huang L; Fan XX; Yao XJ; Xie Y; Li N; Liu L; He JX; Leung EL
    Oncol Rep; 2016 Jul; 36(1):365-75. PubMed ID: 27121230
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overall signature of acquired KRAS gene changes in advanced non-small cell lung cancer patient with EGFR-TKI resistance.
    Zheng J; Dou Y; Huang D; Wang Y; Han R; Hu C; Zhu M; Lu C; Lin C; Wu D; Liu Y; Tang H; He T; Jiang W; He Y
    Jpn J Clin Oncol; 2024 Jan; 54(1):89-96. PubMed ID: 37721193
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ganoderma microsporum immunomodulatory protein combined with KRAS
    Hua WJ; Hwang WL; Yeh H; Lin ZH; Hsu WH; Lin TY
    Int J Biol Macromol; 2024 Feb; 259(Pt 2):129291. PubMed ID: 38211909
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas.
    Baldelli E; El Gazzah E; Moran JC; Hodge KA; Manojlovic Z; Bassiouni R; Carpten JD; Ludovini V; Baglivo S; Crinò L; Bianconi F; Dong T; Loffredo J; Petricoin EF; Pierobon M
    Genes (Basel); 2021 Sep; 12(9):. PubMed ID: 34573384
    [No Abstract]   [Full Text] [Related]  

  • 33. SOS2 modulates the threshold of EGFR signaling to regulate osimertinib efficacy and resistance in lung adenocarcinoma.
    Theard PL; Linke AJ; Sealover NE; Daley BR; Yang J; Cox K; Kortum RL
    Mol Oncol; 2024 Mar; 18(3):641-661. PubMed ID: 38073064
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nutlin-3a induces KRAS mutant/p53 wild type lung cancer specific methuosis-like cell death that is dependent on GFPT2.
    Kim D; Min D; Kim J; Kim MJ; Seo Y; Jung BH; Kwon SH; Ro H; Lee S; Sa JK; Lee JY
    J Exp Clin Cancer Res; 2023 Dec; 42(1):338. PubMed ID: 38093368
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies.
    Khan S; Budamagunta V; Zhou D
    Adv Cancer Res; 2023; 159():145-184. PubMed ID: 37268395
    [TBL] [Abstract][Full Text] [Related]  

  • 36. APE1 stimulates EGFR-TKI resistance by activating Akt signaling through a redox-dependent mechanism in lung adenocarcinoma.
    Lu GS; Li M; Xu CX; Wang D
    Cell Death Dis; 2018 Oct; 9(11):1111. PubMed ID: 30382076
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SLC39A5 promotes lung adenocarcinoma cell proliferation by activating PI3K/AKT signaling.
    Liu Z; Hu Z; Cai X; Liu S
    Pathol Res Pract; 2021 Aug; 224():153541. PubMed ID: 34252710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.
    Loboda A; Nebozhyn M; Klinghoffer R; Frazier J; Chastain M; Arthur W; Roberts B; Zhang T; Chenard M; Haines B; Andersen J; Nagashima K; Paweletz C; Lynch B; Feldman I; Dai H; Huang P; Watters J
    BMC Med Genomics; 2010 Jun; 3():26. PubMed ID: 20591134
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alveolar Differentiation Drives Resistance to KRAS Inhibition in Lung Adenocarcinoma.
    Li Z; Zhuang X; Pan CH; Yan Y; Thummalapalli R; Hallin J; Torborg S; Singhal A; Chang JC; Manchado E; Dow LE; Yaeger R; Christensen JG; Lowe SW; Rudin CM; Joost S; Tammela T
    Cancer Discov; 2024 Feb; 14(2):308-325. PubMed ID: 37931288
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined treatment of ABT199 and irinotecan suppresses KRAS-mutant lung cancer cells.
    Xu Y; Zong S; Gao X; Zhang H; Wang B; Li P; Liu T; Li S
    Gene; 2019 Mar; 688():1-6. PubMed ID: 30415007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.